Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F11 | P03951 | 20/20 | 0.92 |
| ▸ | F10 | P00742 | 5/20 | 0.76 |
| ▸ | PLG | P00747 | 4/20 | 0.76 |
| ▸ | PLAT | P00750 | 4/20 | 0.76 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.75 |
| ▸ | F9 | P00740 | 2/20 | 0.75 |
| ▸ | PROC | P04070 | 2/20 | 0.71 |
| ▸ | F2 | P00734 | 1/20 | 0.67 |
| ▸ | PLAU | P00749 | 1/20 | 0.67 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.67 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.67 |
| ▸ | F7 | P08709 | 1/20 | 0.67 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL480363 | 1.00 | F11 (0.92) | F11F10PLGPLATKLKB1 | |
| SCHEMBL939384 | 1.00 | F11 (0.92) | F11F10PLGPLATKLKB1 | |
| SCHEMBL480362 | 1.00 | F11 (0.92) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478561 | 0.96 | F11 (1.00) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478560 | 0.96 | F11 (1.00) | F11F10PLGPLATKLKB1 | |
| SCHEMBL12945543 | 0.91 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478300 | 0.91 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478298 | 0.91 | F11 (0.89) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478604 | 0.91 | F11 (0.92) | F11F10PLGPLATKLKB1 | |
| SCHEMBL478730 | 0.91 | F11 (0.92) | F11F10PLGPLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324199-B2 | Pyridazine derivatives as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-12-04 | — | — | US | disclosed |
| EP-2265601-B1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021492-A1 | PYRIDAZINE DERIVATIVES AS FACTOR XIA INHIBITORS | F11, F12, TFPI2 | F11 1/4885F10 14/4885PLG 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.